Immunome annual net debt
2019
2020
2022
2023
2024
2025
Immunome Net Debt Growth & History (IMNM)
Immunome's net debt was −$649.6M for fiscal 2025.
View full Immunome company overviewImmunome annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$649.6M | −$511.1M | — |
| 2024 | 2024-12-31 | −$138.5M | −$41.5M | — |
| 2023 | 2023-12-31 | −$97.0M | −$77.0M | — |
| 2022 | 2022-12-31 | −$20.0M | — | — |
| 2020 | 2020-12-31 | −$39.3M | −$37.0M | — |
| 2019 | 2019-12-31 | −$2.3M | — | — |
Immunome quarterly net debt
Q4.19
Q3.20
Q4.20
Q1.21
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$213.0M | −$73.2M | — |
| Q1 2026 | 2026-03-31 | −$579.0M | −$326.2M | — |
| Q4 2025 | 2025-12-31 | −$649.6M | −$511.1M | — |
| Q3 2025 | 2025-09-30 | −$268.6M | −$115.8M | — |
| Q2 2025 | 2025-06-30 | −$139.7M | $22.8M | — |
| Q1 2025 | 2025-03-31 | −$252.8M | $15.7M | — |
| Q4 2024 | 2024-12-31 | −$138.5M | −$41.5M | — |
| Q3 2024 | 2024-09-30 | −$152.8M | — | — |
| Q2 2024 | 2024-06-30 | −$162.6M | — | — |
| Q1 2024 | 2024-03-31 | −$268.5M | — | — |
| Q4 2023 | 2023-12-31 | −$97.0M | — | — |
| Q1 2021 | 2021-03-31 | −$35.8M | — | — |
| Q4 2020 | 2020-12-31 | −$39.3M | −$37.0M | — |
| Q3 2020 | 2020-09-30 | −$6.2M | — | — |
| Q4 2019 | 2019-12-31 | −$2.3M | — | — |
Immunome net debt trends
Over the last five fiscal years, Immunome's net debt decreased from −$39.3M to −$649.6M, a change of −$610.4M. The latest reported quarter, Q2 2026, shows −$213.0M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome source filings ↗